直击业绩会丨康希诺2024年净亏损收窄74.45% 流脑疫苗的未来是扩龄和出海

每日经济新闻
27 Mar

每经记者 林姿辰 每经编辑 张海妮经历连续两年的“营收、净利润双双下降”之后,康希诺(SH688185)终于重回增长轨道。根据公司3月25日发布的年报,康希诺2024年实现营业收入8.46亿元,同比增长137.01%;归母净利润亏损3.79亿元,同比减亏74.45%。对于收入增长,康希诺给出了两个原因:一是公司经营受全球公共卫生事件的影响已基本消除;二是核心产品“曼海欣”的销量快速增长,其中...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10